Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 2245 total matches.

Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010  (Issue 1331)
Important Copyright Message IN THIS ISSUE (starts on next page) Bepotastine (Bepreve) – An Ophthalmic H 1 ...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2 | Show Introduction Hide Introduction

Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like ...
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).
Med Lett Drugs Ther. 2017 Sep 11;59(1529):147-9 | Show Introduction Hide Introduction

Lixisenatide for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide ...
The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-daily treatment of adults with type 2 diabetes, both alone (Adlyxin) and in a fixed-ratio combination with insulin glargine (Soliqua 100/33). Lixisenatide has been available since 2013 in many other countries as Lyxumia. It is the fifth GLP-1 receptor agonist to be approved in the US.
Med Lett Drugs Ther. 2017 Jan 30;59(1513):19-21 | Show Introduction Hide Introduction

Clindamycin-Tretinoin (Veltin Gel) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010  (Issue 1353)
combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025 ...
Veltin Gel (Stiefel), a fixed-dose combination of the antibiotic clindamycin phosphate 1.2% and the retinoid tretinoin 0.025%, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old. Another product containing the same active ingredients (Ziana) has been on the market since 2006.
Med Lett Drugs Ther. 2010 Dec 13;52(1353):102-3 | Show Introduction Hide Introduction

Ertugliflozin for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
as monotherapy or in addition to other drugs, they reduce A1C by 0.5-1%. SGLT2 inhibitors also reduce systolic ...
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Med Lett Drugs Ther. 2018 Apr 23;60(1545):70-2 | Show Introduction Hide Introduction

Brinzolamide/Brimonidine (Simbrinza) for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2013  (Issue 1421)
such as hyperemia, burning, foreign body sensation and allergy may be difficult to tolerate. A 0.1% and 0.15 ...
The FDA has approved Simbrinza (Alcon), an ophthalmic combination of the carbonic anhydrase inhibitor brinzolamide and the selective alpha2-adrenergic receptor agonist brimonidine, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Simbrinza is the first product to combine drugs from these 2 classes.
Med Lett Drugs Ther. 2013 Jul 22;55(1421):57-8 | Show Introduction Hide Introduction

Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third longacting human insulin ...
The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine (Lantus, Toujeo) were approved earlier.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):163-4 | Show Introduction Hide Introduction

Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
-chain that increases its activity against Pseudomonas aeruginosa.1 Tazobactam inhibits most class ...
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in adults.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):31-3 | Show Introduction Hide Introduction

Vuity - Pilocarpine Ophthalmic Solution for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia The FDA has approved Vuity (Abbvie), a 1 ...
The FDA has approved Vuity (Abbvie), a 1.25% ophthalmic solution of the muscarinic receptor agonist pilocarpine hydrochloride, for treatment of presbyopia in adults. Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local and systemic adverse effects have limited their use.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):17-8 | Show Introduction Hide Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
not respond to topical combination therapy, addition of an oral tetracycline is recommended.1,2 The most ...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 | Show Introduction Hide Introduction